The CTIC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CTIC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CTIC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CTIC Detailed Price Forecast - CNN Money||View CTIC Detailed Summary - Google Finance|
|View CTIC Detailed Summary - Yahoo! Finance||View CTIC Stock Research & Analysis - Zacks.com|
|View CTIC Trends & Analysis - Trade-Ideas||View CTIC Major Holders - Barrons|
|View CTIC Call Transcripts - NASDAQ||View CTIC Breaking News & Analysis - Seeking Alpha|
|View CTIC Annual Report - CompanySpotlight.com||View CTIC OTC Short Report - OTCShortReport.com|
|View CTIC Fundamentals - TradeKing||View CTIC SEC Filings - Bar Chart|
|View Historical Prices for CTIC - The WSJ||View Performance/Total Return for CTIC - Morningstar|
|View the Analyst Estimates for CTIC - MarketWatch||View the Earnings History for CTIC - CNBC|
|View the CTIC Earnings - StockMarketWatch||View CTIC Buy or Sell Recommendations - MacroAxis|
|View the CTIC Bullish Patterns - American Bulls||View CTIC Short Pain Metrics - ShortPainBot.com|
|View CTIC Stock Mentions - StockTwits||View CTIC Stock Mentions - PennyStockTweets|
|View CTIC Stock Mentions - Twitter||View CTIC Investment Forum News - Investor Hub|
|View CTIC Stock Mentions - Yahoo! Message Board||View CTIC Stock Mentions - Seeking Alpha|
|View Insider Transactions for CTIC - SECform4.com||View Insider Transactions for CTIC - Insider Cow|
|View CTIC Major Holdings Summary - CNBC||View Insider Disclosure for CTIC - OTC Markets|
|View Insider Transactions for CTIC - Yahoo! Finance||View Institutional Holdings for CTIC - NASDAQ|
|View CTIC Stock Insight & Charts - FinViz.com||View CTIC Investment Charts - StockCharts.com|
|View CTIC Stock Overview & Charts - BarChart||View CTIC User Generated Charts - Trading View|
What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?
Posted on Wednesday April 18, 2018
The latest earnings announcement CTI BioPharma Corp’s (NASDAQ:CTIC) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
Wired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology
Posted on Tuesday March 13, 2018
Stock Monitor: Fate Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on CTI BioPharma Corp. (NASDAQ: CTIC ). ...
CTI BioPharma to Present at Upcoming Investor Conferences
Posted on Friday March 09, 2018
SEATTLE , March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences ...
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Posted on Friday March 09, 2018
SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy (BAT), which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis and thrombocytopenia (defined as platelet counts ≤100 x 109/L). In the intent-to-treat patient population of the study, the combined pacritinib arms (400mg once daily and 200mg twice daily dosing, 149 patients total) demonstrated a significant improvement of 35% or more in spleen volume reduction (SVR) at 24 weeks of treatment in 27 patients (18%) compared to 2 patients (3%) out of 72 patients in the BAT arm, which included treatment with ruxolitinib (P=0.001).